Cerus Corporation Announces New Clinical Trial to Compare Fibrinogen Treatments for Trauma Patients
Cerus Corporation has launched a clinical trial named CRYO-FIRST to compare the efficacy of pre-thawed INTERCEPT Fibrinogen Complex (IFC) with conventional cryoprecipitated antihemophilic factor (CRYO-AHF) in trauma patients with hemorrhagic shock. The study will involve 320 patients and is funded by the U.S. Department of Defense. It aims to provide insights into early fibrinogen transfusion benefits, with results expected to inform treatment for acute trauma patients with fibrinogen deficiency.
Cerus Corporation has announced a new clinical study, CRYO-FIRST, to evaluate the efficacy of pre-thawed INTERCEPT Fibrinogen Complex (IFC) compared to conventional cryoprecipitated antihemophilic factor (CRYO-AHF) in patients experiencing trauma-associated hemorrhagic shock. The study will involve 320 patients and will use hospital cluster randomized treatment blocks to assess the effectiveness of the two FDA-approved blood components. Patients admitted within 60 minutes of a trauma injury and showing low fibrinogen levels will be eligible for the study. The additional funding from the U.S. Department of Defense supports this research, aiming to provide insights into the benefits of early fibrinogen transfusion. The results of the CRYO-FIRST study are expected to offer critical information regarding the treatment of acute trauma patients with fibrinogen deficiency, and findings will be presented in the future. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250721154296) on July 21, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
